Oncotelic Therapeutics Inc. OTLC Archives

MondayOct 26, 2026 9:10 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Peer-Reviewed Study Identifying Four-Gene Signature in Liver Cancer Using AI Platform

Oncotelic Therapeutics (OTCQB: OTLC) announced the publication of a peer-reviewed study in Biomedicines demonstrating how its AI-powered PDAOAI platform helped identify a four-gene prognostic signature in hepatocellular carcinoma ("HCC"), a form of liver cancer. Published Oct. 23, 2026, the study used Partitioned Literature Aggregation ("PLA"), Oncotelic's patented algorithm running on PDAOAI, alongside gene-expression and survival analyses to identify four genes: FKBP1A, EIF4E, RRAGC and PPARGC1A. The signature's association with patient survival was independently validated in a Japanese HCC cohort of 203 patients. The findings support patient stratification for clinical trials of Sapu003, an intravenous formulation of everolimus. Oncotelic Chief Business…

TuesdayOct 20, 2026 9:00 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present AI-Enabled Drug Discovery Keynote at 22nd Drug Discovery Strategic Summit

Oncotelic Therapeutics (OTCQB: OTLC) announced that Chief Business Officer Saran Saund will deliver the opening keynote on the second day of the 22nd Drug Discovery Strategic Summit on Oct. 22, 2026, at 9 a.m. Pacific Time in Millbrae, California. The presentation will explore partition and aggregation as an organizing principle for AI-enabled drug discovery, emphasizing how complex research questions can be divided into focused investigations and findings combined to develop testable hypotheses. Saund will discuss the company's proprietary PDAOAI platform, which indexes approximately 29 million PubMed abstracts, along with its international intellectual property strategy, planned expansion into genetic discovery and…

ThursdayOct 15, 2026 10:30 am

Oncotelic Highlights PDAOAI Discovery Platform and HCC Research at Drug Discovery 2026

Scott Myers described how PDAOAI searches and organizes an index of approximately 29 million PubMed abstracts to support focused biomedical research. Saran Saund presented a four-gene HCC signature associated with survival in an exploratory discovery analysis and an independent Japanese cohort. BIO REBOOT connects the platform’s research capabilities with potential funding and development support for selected projects. Oncotelic Therapeutics Inc. (OTCQB: OTLC) (“Oncotelic”) is pursuing a development strategy that connects biomedical literature analysis with the practical work of developing therapeutics. At Drug Discovery 2026 in Burlingame, California, Scott Myers and Saran Saund showed how the company’s PDAOAI platform can help…

MondayAug 03, 2026 9:50 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present at OTCQB Virtual Investor Conference

Oncotelic Therapeutics (OTCQB: OTLC) announced that CEO and Chairman Dr. Vuong Trieu will present at the OTCQB Virtual Investor Conference on Aug. 6, 2026, at 2:30 p.m. ET, where investors will have the opportunity to participate in a live question-and-answer session. The company will highlight recent progress, including advancement of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort, expansion of European clinical sites, validation of its Deciparticle(TM) platform through peer-reviewed publications, scalable cGMP manufacturing capabilities and continued development of its AI-driven drug discovery, robotics and nanomedicine platforms. To view the full press release, visit https://ibn.fm/fGHUt About…

WednesdayJul 15, 2026 2:43 pm

QualityStocksNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Brings AI and Robotics Together in New Platform

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed the company’s launch of an AI-powered manufacturing services platform designed to help emerging biotechnology companies overcome one of the industry’s biggest challenges: accessing full GMP infrastructure. “The platform combines Oncotelic’s proprietary PDAOAI(TM) architecture with digital manufacturing technologies and intelligent robotics developed in collaboration with TechForce Robotics, the company’s strategic robotics and automation partner. The goal is not simply to apply AI to drug discovery, but to bring it into the manufacturing workflows that determine whether a therapy moves efficiently from development toward commercialization.” Already deployed at Oncotelic’s GMP-certified SAPU manufacturing facility to…

ThursdayJul 09, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Targets Biotech’s Manufacturing Bottleneck with AI-Powered GMP Platform

Oncotelic has launched an AI-powered GMP manufacturing services platform that integrates its PDAOAI(TM) architecture, digital batch records, and intelligent robotics built with partner TechForce Robotics The platform targets emerging biotechs, CDMOs, cell and gene therapy developers, and radiopharmaceutical manufacturers that cannot justify building full GMP infrastructure in-house The same AI-GMP capabilities already run inside Oncotelic's SAPU manufacturing base, positioning the launch as both a pipeline accelerator and a potential new revenue line For emerging biotechnology companies, the road from promising science to clinical execution often breaks down in the same place: manufacturing. Discovery can begin in a university lab, a…

WednesdayJun 24, 2026 1:51 pm

QualityStocksNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Eyes Opportunity Through AI and Pharmaceutical Automation

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed the company’s efforts to move beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. The publication reads, “Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments… At the core of this pivot is Oncotelic’s proprietary PDAOAI platform, an AI-driven system designed to improve compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing expertise,…

TuesdayJun 23, 2026 10:30 am

The $410 Billion Drug Delivery Revolution: Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation

The rapidly expanding nanomedicine and advanced drug-delivery market is attracting growing attention as pharmaceutical companies seek ways to improve therapeutic performance without relying solely on costly new drug discovery programs. By addressing challenges such as poor bioavailability, inconsistent pharmacokinetics and limited tumor penetration, nanotechnology-based delivery systems may unlock additional value from existing oncology drugs. Oncotelic Therapeutics' Deciparticle(TM) platform and Sapu003 program illustrate how innovative drug delivery approaches could help reshape the future of cancer treatment. The search for new cancer therapies has traditionally focused on discovering entirely new drug candidates. While this approach has produced important breakthroughs, it is also…

ThursdayJun 18, 2026 9:00 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Launches AI-Powered GMP Manufacturing Services Platform at BIO 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform combines the company's PDAOAI™ technology with advanced robotics provided through its collaboration with TechForce Robotics to support pharmaceutical, biotechnology and advanced therapeutics companies seeking to modernize manufacturing operations through AI-driven workflows, digital quality systems and intelligent automation. Oncotelic said the platform is designed to support electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions and process monitoring. The company will also showcase progress with its Deciparticle™ nanomedicine platform, including…

WednesdayJun 17, 2026 9:00 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances AI-Powered GMP Manufacturing Platform

Oncotelic Therapeutics (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing commercialization of an AI-powered good manufacturing practices manufacturing services platform at SAPU Bio, the company's 45%-owned sterile injectable cGMP manufacturing joint venture. The Phase 2 deployment expands the capabilities of Oncotelic's proprietary PDAOAI(TM) platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement. The company said the integrated platform combines PDAOAI(TM) with TechForce's autonomous robotic systems to support intelligent pharmaceutical manufacturing and create potential opportunities in software licensing, automation deployment, manufacturing partnerships…

Site Search

Company Search

Tag: Oncotelic Therapeutics Inc. OTLC